Norwegian version of this page

Pharmacokinetics (PK-group)

The research vision in the pharmacokinetics (PK)-group is “the right drug at the right dose to each patient”. We perform both basal and clinical research.

Image may contain: Output device, Font, Thumbs signal, Gadget, Circle.

About the group

Differences in drug response between individuals is a common and well-known clinical problem. The same dose of a drug can be effective and safe in one patient and give rise to side effects or therapeutic failure in another. In order to tailor drug treatment for the individual patient, it is necessary to increase our knowledge about causes of variability in drug response between individuals.

Our research groups work within the field of pharmacokinetics with a special focus on individualized drug treatment. The common goal of our projects is to characterize various factors that are important variability in drug response, including genetic variability in drug metabolizing enzymes and drug transporters, disease related factors, drug-drug interactions and gut microbiome composition. We have also implemented different modelling software to investigate pharmacokinetic associations, utilizing both population modelling and in vitro-in vivo extrapolations.

Over many years, we have had close collaboration with several clinical research groups, and therefore access to patient material to test our hypotheses. Thus, we have unique opportunities to study the relevance of our molecular research findings in a clinical context.

Research projects

  • Influence of gut microbiome on drug dosing
  • CYP3A-activity in different patient populations
  • Individualized dosing of immunosuppressive drugs
  • Drug metabolism (in vitro)
  • Pharmacokinetic modelling

Read more about our projects.


The PK-group has a close collaboration with several clinical research groups and performs many clinical studies in different patient populations. We have for instance performed several studies on immunosuppressive drugs in solid organ transplant recipients and pharmacokinetic studies in patient with severe obesity and in children.

Read more about our collaboration.

Follow us on Instagram


Published Nov. 9, 2010 12:03 AM - Last modified Aug. 3, 2022 2:40 PM